ABSTRACT
BACKGROUND: Garenoxacin is a des-F(6)-quinolone with in vitro activity against key respiratory pathogens, including Streptococcus pneumoniae, Hemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis. Limited data are available regarding the effect of garenoxacin in the treatment of acute bacterial sinusitis. OBJECTIVE: The aim of this study was to assess the efficacy and tolerability of garenoxacin in adults with acute bacterial maxillary sinusitis undergoing a pre-treatment diagnostic sinus aspirate. METHODS: This Phase II, multicenter, noncomparative, open-label study was conducted at 30 centers in the United States, Mexico, Argentina, and Europe. Male and female patients aged 18 to 80 years with clinical signs and symptoms lasting >or=5 but Subject(s)
Anti-Bacterial Agents/administration & dosage
, Bacterial Infections/complications
, Fluoroquinolones/administration & dosage
, Maxillary Sinus/drug effects
, Maxillary Sinusitis/drug therapy
, Acute Disease
, Administration, Oral
, Adult
, Aged
, Anti-Bacterial Agents/adverse effects
, Argentina
, Bacterial Infections/drug therapy
, Bacterial Infections/microbiology
, Biopsy, Needle
, Drug Administration Schedule
, Europe
, Female
, Fluoroquinolones/adverse effects
, Humans
, Male
, Maxillary Sinus/microbiology
, Maxillary Sinusitis/microbiology
, Middle Aged
, North America
, Treatment Outcome